NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
April 13, 2004 • Volume 1 / Number 15 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Funding OpportunitiesFunding Opportunities

Notice of Availability of Administrative Supplements for Disseminating Evidence-Based Intervention Research Products

Application Receipt Dates: June 30, 2004

NCI is requesting applications for administrative supplements for NCI-funded cancer control intervention research R01, P01, P50, U01, and U19 grants. These supplements have been designed to provide 1-year funding to cancer control investigators whose intervention efficacy data have been analyzed and who are conducting peer-reviewed research (with an active NCI grant award) related to the intervention program proposed for dissemination.

The supplements will support R01, P01, P50, U01, and U19 award mechanisms.

For more information see

Inquiries should be addressed to the NCI Program Director for the particular R01, P01, P50, U01, or U19 for which the supplement is being requested.

Inter-Institute Program for the Development of AIDS-Related Therapeutics

Letter of Intent Receipt Date: May 1, 2004
Application Receipt Date: June 1, 2004

The Inter-Institute Program (IIP) for the Development of AIDS-Related Therapeutics is cosponsored by the National Institute of Allergy and Infectious Diseases and NCI. Investigators are invited to submit proposals to this therapeutics development program. The IIP is designed to help AIDS research investigators facilitate the preclinical development of: (1) therapies for the treatment of HIV disease, AIDS-associated malignancies, opportunistic infections, and tuberculosis associated with AIDS and (2) microbicide-based prevention strategies for HIV.

The IIP does not fund grants but instead provides IIP drug development resources.

For more information see

Inquiries: Inter-Institute Program Coordinator,